For decades, the pharmacological management of social anxiety disorder (SAD) has been tethered to a rigid paradigm: daily, chronic dosing of SSRIs or SNRIs that take weeks to reach therapeutic efficacy. But a new intranasal neuroactive compound is challenging that status quo, offering a glimpse into the future of acute, on-demand psychiatric relief.

Vistagen Therapeutics announced positive topline results from an exploratory Phase 2 clinical trial evaluating its repeat-dose fasedienol nasal spray for the acute treatment of anxiety triggered by public speaking. The trial, which enrolled 61 adults with SAD, represents a critical pivot away from prophylactic daily regimens toward a model of situational, as-needed intervention.

The Public Speaking crucible

Participants in the multicenter, randomized, double-blind study were subjected to a standardized public speaking challenge—a classic stressor for those grappling with performance anxiety. They received either two 3.2 µg doses of fasedienol administered ten minutes apart, a single dose, or a placebo. The primary objective was to evaluate the safety and tolerability of repeat dosing, which the company reported was favorable and comparable to single-dose treatment, with no new safety findings.

While the primary endpoint—the change in Subjective Units of Distress Scale (SUDS) scores—did not reach statistical significance across the broader cohort (p=0.10), the data revealed a nuanced and highly encouraging signal among patients with very severe disease.

In a prespecified subgroup analysis of patients with very severe SAD (defined by a baseline Liebowitz Social Anxiety Scale score of 95 or higher), pooled fasedienol reduced SUDS scores by 16.2 points compared with just 1.6 points for placebo, achieving nominal statistical significance (p=0.04). Furthermore, repeat-dose fasedienol reduced anticipatory anxiety immediately before the speaking challenge by 19.3 points versus 0.9 points for placebo (p=0.01).

A $2.5 Billion Market imperative

The clinical logic behind fasedienol is genuinely distinct from approved pharmacotherapy options like paroxetine or venlafaxine, which work through monoaminergic mechanisms that take weeks to engage. Fasedienol, which already carries FDA Fast Track designation, targets a faster-acting neurocircuitry pathway. With the global acute SAD market projected to reach $2.5 billion by 2034, driven by rising diagnostic rates among younger demographics, an on-demand option could catalyze a major shift in how situational anxiety is managed. Chief Medical Officer Dr. Angel Angelov noted that these pronounced benefits in severe patients mirror results from previous Phase 3 trials and will directly guide upcoming regulatory discussions with the FDA. Follow the latest psychiatric drug development via Pharmacally and Vistagen Therapeutics on X.

Related Topics:

#Mental Health#FDA#Clinical Trials#Social Anxiety Disorder#Fasedienol#Vistagen Therapeutics#Psychiatric Medications
benjamin
benjaminStaff Writer

Related Articles

Comments (0)

No comments yet. Be the first to share your thoughts!